The appeal of cerasomes begins with the limitations of conventional carriers. Liposomes, which are spherical structures assembled from phospholipids, can accommodate water-soluble compounds in their internal aqueous compartment and fat-soluble compounds within the membrane. They are generally biocompatible and their surfaces can be chemically modified, but they may fuse with one another, aggregate, leak their cargo and disappear rapidly from circulation. Silica nanoparticles offer a contrasting set of strengths, including structural integrity, tunable surfaces, high areas for chemical attachment and resistance to some environmental stresses. Yet purely inorganic particles can be less flexible, less biomimetic and less suitable for certain drugs. Cerasomes are designed as a compromise: a lipid-based vesicle is reinforced from the outside by an interconnected siloxane network, producing a structure that remains biologically versatile while resisting deformation and premature breakdown.

The concept traces back to work on organic–inorganic hybrid materials and to the first cerasomes reported by Katagiri and collaborators in 2007. The particles are made from specialized cerasome-forming lipids containing silicon-bearing head groups, hydrophobic hydrocarbon tails and molecular linkers. In water, these amphiphilic molecules can organize into a bilayer, much as ordinary lipids do. Their silicon-containing groups then undergo hydrolysis and condensation reactions, the central chemical steps of a sol–gel process. Hydrolysis converts reactive alkoxysilane groups into silanol groups, while condensation connects them through Si–O–Si bonds. The resulting polyorganosiloxane layer forms over the vesicle surface rather than replacing the membrane. This architecture gives the particle an organic interior and an inorganic exterior, with the thickness and properties of each component influenced by the molecular structure of the starting lipids.

The review describes two broad preparation routes. In one, cerasome-forming lipids are dispersed directly in water, often by vortex mixing, allowing vesicle formation and surface rigidification to occur in the same environment. In another, the lipids are first incubated in acidic ethanol so that their silicon-containing groups hydrolyze before the solution is injected into water. Sonication can reduce multilamellar structures and produce smaller vesicles, while subsequent incubation and drying help complete formation of the hybrid network. The exact outcome depends strongly on pH, temperature, solvent composition, precursor concentration and hydrolysis time. These variables affect condensation, particle size, surface charge, encapsulation efficiency and release kinetics. That sensitivity is scientifically useful because it permits tuning, but it also creates a reproducibility problem when researchers attempt to move from small laboratory batches to industrial production.

Once formed, a cerasome can carry several kinds of cargo at the same time or in different formulations. Hydrophilic drugs can be enclosed in the aqueous core, whereas hydrophobic compounds can lodge in the lipid region. Amphiphilic molecules can interact with both environments. The siloxane shell restricts membrane motion and creates a barrier that can reduce leakage, extending release over hours or days depending on composition and cross-linking. In examples summarized by the authors, doxorubicin-loaded cerasomes retained about 92 percent of their encapsulated drug after 90 days of storage, compared with approximately 35 percent for conventional liposomes. Paclitaxel-loaded cerasomes also released the drug more slowly than paclitaxel-loaded liposomes under laboratory conditions. Such results suggest that stability can be a practical advantage, although a release rate that is too slow could prevent enough drug from reaching its intended target.

Surface chemistry provides a second level of control. Cerasome surfaces contain reactive silanol groups that can be modified with polymers, peptides, antibodies, aptamers, fluorophores or other molecules. The review describes a route in which 3-aminopropyltriethoxysilane introduces exposed amino groups, followed by glutaraldehyde chemistry that creates attachment sites for targeting ligands and imaging agents. Polyethylene glycol can make the surface more hydrophilic, reduce aggregation and extend circulation. Folic acid, peptides and antibodies can be added to recognize receptors that are unusually abundant on particular cancer cells. HER2-directed cerasomes, for example, have been investigated as carriers for doxorubicin in HER2-positive breast cancer models. Other designs use triphenylphosphonium to direct cargo toward mitochondria, where disrupting energy production can intensify cancer-cell damage. These strategies are intended to improve selectivity, but the biological identity of any nanoparticle can change after proteins from blood coat its surface.

Cerasomes can also be engineered to respond to conditions associated with disease or intracellular trafficking. Tumour tissue and endosomal compartments are often more acidic than blood, creating an opportunity for pH-sensitive release. Redox-responsive designs exploit reducing conditions and elevated glutathione concentrations inside cells, which can cleave specially designed linkages and promote release after uptake. Temperature-sensitive formulations have been studied for treatments that use localized heating, while light-responsive systems can provide remote control where the activating wavelength can reach the tissue. Near-infrared light is attractive because it penetrates more deeply than ultraviolet or visible light, although tissue penetration remains a constraint. Ultrasound-responsive cerasomes represent another approach, allowing externally applied energy to trigger local effects. The review notes that dual-responsive particles, such as systems reacting to both pH and redox conditions, may offer finer control than single-trigger carriers.

The same structural features that make cerasomes attractive for drugs also broaden their potential uses. Positively charged cerasomes can bind plasmid DNA, small interfering RNA and other nucleic acids, while their partial ceramic coating helps prevent fusion with other vesicles and protects cargo from premature degradation. A reported cerasome–DNA complex was about 70 nanometres across, a size that can support cellular uptake and intracellular trafficking. The particles have also been explored for cancer theranostics, a combination of diagnosis and treatment. Fluorescent dyes, quantum dots, magnetic nanoparticles and porphyrins can be incorporated into or attached to the vesicles, enabling optical imaging, magnetic resonance imaging or photodynamic therapy. In vaccine delivery, the hybrid shell may protect antigens and improve storage stability, while surface ligands could help direct antigens toward antigen-presenting cells. Related investigations have considered insulin delivery, antimicrobial applications, neurodegenerative disease and precision medicine.

Yet the review’s most important message may be its account of the obstacles between promising experiments and medical products. Silica-containing materials can accumulate in organs such as the liver and spleen, so researchers must establish how composition, size, charge and surface chemistry influence toxicity, inflammation, biodistribution and elimination. Cerasomes can gradually hydrolyze, producing soluble silicic-acid species, but their degradation depends on the structure and the surrounding biological environment. Protein-corona formation may alter targeting and circulation in ways that are still poorly understood for this specific class of particles. Manufacturing presents another challenge: conventional methods can produce batch-to-batch variation in size, charge, shell formation and drug loading. Microfluidic and continuous-flow methods may improve mixing and reproducibility, while quality-by-design approaches could link manufacturing conditions to critical product properties. For now, the authors conclude, cerasomes are promising next-generation nanocarriers rather than established therapies. Standardized characterization, extensive animal studies, long-term safety testing and carefully designed clinical investigations will determine whether their unusual marriage of lipid biology and silica chemistry can deliver on its therapeutic promise.

The cerasome architecture is important because it separates several design functions within one particle. The lipid bilayer supplies a water-compatible interior and a hydrophobic domain, while the polysiloxane framework provides a chemically addressable outer surface. This compartmentalization allows researchers to select cargo according to its physicochemical properties rather than forcing every therapeutic molecule into the same environment. It also creates opportunities to adjust membrane composition, shell formation and surface chemistry independently, although changes in one component may influence the stability, permeability and biological behaviour of the whole nanostructure.

Surface functionalization can be understood as a way of regulating interactions at the biological interface. Silanol groups on the silica-containing exterior provide sites for chemical modification, potentially enabling attachment of ligands that recognize cellular receptors or polymers that alter colloidal behaviour. Such modifications do not guarantee selective delivery: targeting molecules must remain accessible in biological fluids, and the particle must still circulate, reach the relevant tissue, bind to cells and undergo uptake. Consequently, the performance of a targeted cerasome depends not only on ligand choice but also on particle size, surface charge, ligand density and the stability of the coating under physiological conditions.

The review places cerasomes within a broader progression in nanocarrier design, from single-function vesicles toward multifunctional systems that combine transport, sensing and treatment. Their ability to incorporate imaging agents alongside therapeutic or genetic cargo supports pharmacokinetic studies and theranostic concepts, in which localization and response might be monitored during treatment. At the same time, multifunctionality increases the number of properties that must be measured and controlled. Meaningful evaluation therefore requires more than demonstrating cargo loading: studies must relate shell chemistry and degradation to release, cellular uptake, biological distribution and eventual clearance. Establishing those relationships will be central to determining whether the advantages of organic–inorganic integration translate into reproducible therapeutic benefit.

Subject of Research: Nanohybrid cerasomes for targeted drug and biomedical delivery

Article Title: Nanohybrid cerasomes as silica lipid carriers for targeted therapeutics

Article References: Sabale, V., Dhage, R., Chawade, S., Kaithwas, A., Nikam, M., & Sabale, P. (2026). Nanohybrid cerasomes as silica lipid carriers for targeted therapeutics. Discover Industrial Chemistry and Materials, 1(1), Article 17. https://doi.org/10.1007/s44508-026-00018-7

Image Credits: AI Generated

DOI: 10.1007/s44508-026-00018-7

Keywords: Cerasomes, Nanomedicine, Drug delivery, Silica nanoparticles, Liposomes, Cancer therapy, Gene delivery, Theranostics, Nanohybrid, silica, lipid, carriers

This innovative approach hinges on the administration of IVIG prior to nanoparticle injection, fundamentally modulating the organism’s immune environment. IVIG comprises a broad spectrum of human immunoglobulin G (IgG) antibodies pooled from healthy donors, widely recognized for their immunomodulatory properties in treating autoimmune and inflammatory diseases. By transiently saturating and effectively blocking the mononuclear phagocyte system (MPS)—the primary component responsible for clearing foreign particles including nanoparticles—IVIG pretreatment reduces the immune system’s ability to recognize and rapidly clear PEGylated nanoparticles from circulation. This mechanism circumvents the problematic anti-PEG antibodies, which are the drivers of the ABC effect, thus maintaining higher systemic levels of nanomedicine and enabling enhanced accumulation at disease-target sites.

The universality of the IVIG pre-intervention strategy is particularly striking, with the study demonstrating its efficacy across a diverse array of nanomaterials that differ both structurally and in size, ranging from 10 to 120 nanometers. This breadth of applicability underscores the potential for widespread clinical translation, as IVIG pretreatment successfully reversed the ABC effect in all tested nanoparticle formulations. Such a versatile solution is vital given the increasing complexity and variety of nanomedicine platforms developed for targeted drug delivery, imaging, and combined therapeutic modalities.

In preclinical models of breast cancer, the benefits of IVIG pretreatment were especially pronounced. The study revealed a notable enhancement in therapeutic efficiency, achieving up to a 3.9-fold increase in efficacy in larger tumors measuring approximately 350 cubic millimeters. This finding not only signifies a remarkable boost in antitumor response but also illuminates a feasible route to improve clinical outcomes in challenging, late-stage cancers where nanoparticle delivery has traditionally been less effective due to biological clearance mechanisms.

The implications of these insights extend beyond the immediate improvement in pharmacokinetics. By enabling multiple doses of PEGylated nanomedicines without eliciting rapid immune clearance, IVIG pretreatment can facilitate long-term treatment strategies critical for chronic diseases such as cancer, autoimmune disorders, and infectious diseases. This strategy reshapes the current paradigm in nanomedicine delivery, highlighting the crucial interplay between immunology and nanotechnology, and providing a clear pathway to circumvent intrinsic immunogenic barriers.

The authors carefully evaluated the immunologic changes induced by IVIG administration and found evidence supporting a transient modulation rather than sustained immunosuppression. This temporally controlled immune alteration is crucial for safety, as it minimizes the risk of prolonged immunodeficiency while allowing enough time for repeated nanoparticle delivery. This fine balance positions IVIG pretreatment as a promising adjunctive treatment that leverages the body’s immunologic plasticity, paving the way for enhanced precision nanomedicine.

An intriguing aspect of the study is the detailed analysis of how IVIG interacts with the MPS. The system comprises phagocytic cells, including macrophages and monocytes within the liver and spleen, which function as the body’s primary defense by scavenging foreign elements from the bloodstream. PEGylated nanoparticles are often recognized by these immune cells due to the formation of anti-PEG antibodies upon repeated exposure. IVIG, with its complex antibody repertoire, saturates the Fc receptors on these phagocytes, effectively blocking the binding and uptake of antibody-labeled nanoparticles. This mechanistic insight opens new avenues for manipulating immune clearance pathways in a controlled and clinically safe manner.

The study’s findings compel a reevaluation of existing nanomedicine delivery protocols, where immunogenic clearance has been an overlooked yet decisive factor impacting clinical translation. The integration of IVIG pretreatment into treatment regimens offers a practical solution leveraging an already clinically approved agent, thereby avoiding the protracted timeline associated with developing novel drugs or formulations. This approach holds immediate promise for accelerating the incorporation of nanomedicines into routine clinical practice with improved reliability and efficacy.

Moreover, this advance challenges the long-standing perception that PEGylation, despite its advantages, inevitably triggers immune responses leading to drug clearance upon repeated dosing. By demonstrating a method to curtail this immune response, the study revives confidence in PEGylated nanomedicine platforms, which have previously faced skepticism due to immunogenicity concerns. Consequently, this could renew research and investment interest into PEGylated systems and spur further innovations in nanoparticle design integrated with immunomodulation strategies.

The study also highlights the future directions where IVIG pretreatment could be combined with other emerging technologies to further fine-tune nanomedicine delivery. For instance, integrating immune checkpoint inhibitors or designing nanoparticles with decoy mechanisms to evade immune detection might synergize with IVIG to produce even more sustained therapeutic windows. The potential for tailoring immune environment modulation in conjunction with nanoparticle engineering holds transformative promise in personalized medicine.

In conclusion, the pioneering work conducted by Lai, He, and colleagues represents a major leap forward in overcoming the immunogenic barriers that have long limited the success of PEGylated nanomedicines. By harnessing IVIG’s immunomodulatory capacity to transiently suppress mononuclear phagocyte activity, they have unlocked a robust method to reverse the ABC effect and enhance drug delivery efficiency across multiple nanomaterial platforms. This clinically ready intervention not only boosts therapeutic outcomes in breast cancer models but also defines a universal framework to improve nanomedicine performance in a range of pathologies requiring repeated drug administration.

As the field moves forward, the synergy between immunology and nanotechnology illustrated here promises to reshape therapeutic landscapes, enabling safer, more effective, and longer-lasting nanomedicine treatments. The translational potential of IVIG pre-intervention is immense, with the likelihood of rapid clinical adoption given the existing approval status of IVIG preparations worldwide. This strategy sets a new standard and a hopeful precedent that immunogenic clearance can be strategically circumvented, offering renewed hope for patients undergoing complex and repeated treatment courses with nanomedicine.

The innovative approach presented in this study thereby not only solves one of nanomedicine’s most vexing obstacles but simultaneously catalyzes a broader conceptual shift: the immune system, once regarded primarily as a barrier, can be transiently modulated to enhance therapeutic delivery without compromising overall host defense. This paradigm shift could open the door to a new generation of nanomedicines optimized not only for their physicochemical properties but also for their interaction with the body’s immune microenvironment, ultimately revolutionizing the precision and efficacy of future therapies.

Subject of Research: Nanomedicine, immunogenic clearance, PEGylated nanoparticles, intravenous immunoglobulin (IVIG), accelerated blood clearance (ABC) effect

Article Title: Pre-intervention with intravenous immunoglobulin reverses the immunogenic clearance of PEGylated nanomedicines.

Article References:

Lai, K., He, P., He, Y. et al. Pre-intervention with intravenous immunoglobulin reverses the immunogenic clearance of PEGylated nanomedicines.
Nat. Biomed. Eng (2026). https://doi.org/10.1038/s41551-026-01661-3

Image Credits: AI Generated

DOI: https://doi.org/10.1038/s41551-026-01661-3